ArticleInternational journal of clinical and experimental medicine2015
High-dose methotrexate plus temozolomide as a salvage treatment in metastatic central nervous system Lymphoma: two cases report and review of literature.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Article
- Curative effect of methotrexate combined with teniposide in the treatment of primary central nervous system lymphoma.Oncology letters · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Temozolomide (TMZ), an alkylating agent, is widely used for treating high-grade gliomas and has emerged as a treatment option for primary central nervous system lymphoma (PCNSL) because of its good penetration of the blood-brain barrier (BBB) and mild toxicity profile. To our knowledge, the role of temozolomide in the treatment of lymphoma was confined to PCNSL and its role in lymphoma central infiltration has not been reported yet. We describe our experience using a combination of high-dose methotrexate and temozolomide (MT) in two metastatic central nervous system Lymphoma (CNSL). As far as we know, this is the first case report about temozolomide in metastatic CNSL patients and no study to date has incorporated investigation of the biology of metastatic CNSL into the treatment protocol. Temozolomide may represent a promising new drug for the treatment of metastatic CNSL.
Indexed as
Identifiers
26221398PMC4509343W2403412605What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.